Appointment dossier — Prostate Adenocarcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Prostate Adenocarcinoma
No studies or cited compounds on file for this cancer yet.
Open recruiting trials (18)
- NCT04134260 · Phase 3 — Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial (United States)
- NCT06022822 · Phase 2 — Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial (United States)
- NCT07179783 · Phase 2 — Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) (China)
- NCT06325046 — Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer (United States)
- NCT07426055 · Phase 2 / Phase 3 — PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer (Poland)
- NCT05969860 · Phase 2 — At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer (United States)
- NCT06683846 · Phase 2 — Ivonescimab in the Treatment of Multiple Advanced Tumors (China)
- NCT07410494 · Phase 1 / Phase 2 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors (China)
- NCT06172478 · Phase 2 — A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors (United States)
- NCT06451497 · Phase 1 — This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors (United States)
- NCT06778863 · Phase 1 — A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation (United States)
- NCT03678025 · Phase 3 — Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer (United States)
- NCT07477626 · Phase 3 — Radiotherapy After Prostatectomy for Node Positive Prostate Cancer (China)
- NCT03824652 · Phase 2 — WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy (United States)
- NCT06844383 · Phase 2 — A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate (United States)
- NCT06636682 · Phase 2 — FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer (United States)
- NCT07332000 · Phase 2 — A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec (United States)
- NCT05790213 · Phase 2 — Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation (United States)
Most-relevant first: trials that name Prostate Adenocarcinoma, then broader trials you may still qualify for. 183 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
Questions to ask your oncologist
- Of the open trials I found (for example NCT04134260), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?